
Arcutis stock rises following litigation stay
Investing.com -- Shares of Arcutis Biotherapeutics (NASDAQ:ARQT), a biopharmaceutical company specializing in immuno-dermatology, surged 10.8% on the day after the announcement of a joint stipulation to stay the ongoing patent litigation with Padagis. This legal development, disclosed on April 2, 2025, has led to the postponement of all scheduled court dates and the trial itself, which was set to ...